FOXP3型
医学
白细胞介素2受体
调节性T细胞
硬皮病(真菌)
系统性硬皮病
流式细胞术
免疫学
结缔组织病
病理
内科学
作者
Sandra Klein,Cosima C. Kretz,Vincent Ruland,Christine Stumpf,Merle Haust,Wolfgang Hartschuh,Martin Hartmann,Alexander Enk,Elisabeth Suri-Payer,Nina Oberle,Peter H. Krammer,Annegret Kuhn
标识
DOI:10.1136/ard.2009.116525
摘要
Objective To determine the frequency and suppressive capacity of regulatory T cells (T reg ) and their association with clinical parameters in patients with systemic scleroderma (SSc). Methods Peripheral blood from 25 patients with SSc, 15 patients with localised scleroderma (LS) and 29 healthy controls (HC) was studied. Analysis of CD4 + forkhead box P3 (Foxp3) + and CD4 + CD25 ++ Foxp3 + Treg subpopulations was carried out by flow cytometry and cell proliferation was quantified by 3 H-thymidine incorporation. Quantitative analysis of T reg was further performed in skin biopsies from 17 patients with SSc and 21 patients with LS using anti-CD4 and anti-Foxp3 monoclonal antibodies for immunohistochemistry. Results The frequency of CD4 + Foxp3 + and CD4 + CD25 ++ Foxp3 + Treg in peripheral blood from patients with SSc was not significantly different from that of patients with LS or HC. The suppressive capacity of CD4 + CD25 ++ Treg in SSc was also found to be similar to that of HC. Phenotypic and functional data revealed no significant difference between the limited or diffuse form of SSc. Moreover, therapy with bosentan showed no significant effect on the frequency of T reg during the course of the disease. However, the frequency of T reg in skin lesions from patients with SSc or LS, determined as the percentage of CD4 + cells expressing Foxp3 in the inflammatory infiltrate, was significantly reduced compared with other inflammatory skin diseases. Conclusion These results indicate that although the authors found no defect in the frequency or function of peripheral T reg subpopulations, the reduction of CD4 + Foxp3 + T reg in the skin of patients with SSc may be important in the pathogenesis of the disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI